Procedure revenue decreased 3.6% year-over-year, ... Biote today is announcing a strategic organizational restructuring designed to drive sustainable growth and create long-term value for ...

Specifically, Biote projects fiscal 2024 revenue of greater than $200 million and Adjusted EBITDA of greater than $60 million. The Company’s 2024 financial guidance includes: (i) procedure ...

Second, we are intensifying our focus on adding new practitioners to further broaden our network and reinvigorate our procedure revenue growth rate. Biote has developed an outstanding training ...

Biote continues to generate strong operating ... an increase of 9.0% from $45.7 million for the fourth quarter of 2023. Procedure revenue grew 5.0%, primarily reflecting growth at established ...

Hurricane Helene caused clinic closures in several core states, impacting third-quarter procedure volumes. Biote Corp (NASDAQ:BTMD) adjusted its 2024 financial guidance downward due to temporary ...

Biote Chief Executive Officer. “Total first quarter revenue increased 4.7% year-over-year, primarily due to a 25.5% increase in dietary supplements revenue. Procedure revenue decreased 3.6% year ...